stockrow
Friday 6 November 2026
Export BCDA’s income statement to Excel — free account
BioCardia, Inc.
BCDA Healthcare Biotechnology
BioCardia, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $477,000.00, up 722.4% from fiscal 2024.
- EPS
- +67.5%
- Free cash flow
- −5.15%
Quarter to June 2026, against a year earlier
0.87
0.02
−2.25%
Follow BCDA
Alert me
BioCardia, Inc. (BCDA) P/E ratio
BioCardia, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 333× (June 2015) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2024 | 0.0× | — |
| Mar 2024 | 0.0× | — |
| Dec 2023 | 0.0× | — |
| Sep 2023 | 0.0× | — |
| 34 more quarters | Free account |
Against its own ten years
Low 0.0×
High 333×
Ten-year median
0.0×
Current reading's percentile
89
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| LPCN Lipocine Inc. compare | n/m |
| ADAPY Adaptimmune Therapeutics PLC compare | n/m |
| TCRX TScan Therapeutics, Inc. compare | n/m |
| BCDA BioCardia, Inc. | n/m |
| CASIF CASI Pharmaceuticals Inc. compare | n/m |
| DYAI Dyadic International Inc. compare | n/m |
| BOLT Bolt Biotherapeutics, Inc. compare | n/m |
| AKTX Akari Therapeutics PLC compare | n/m |
| RADX Radiopharm Theranostics Limited - Sponsored ADR compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)